Diagnosestellung mittels Ultraschall- oder CT-gesteuerter Feinnadelbiopsie, ggf. ERCP, selektive Angiographie. Tumormarker Ca 19–9 in ca. 80% erhöht.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Brennan MF, Kinsella T, Friedman M (1989) Cancer of the Pancreas. In: DeVita V, Heilman S, Rosenberg SA (eds) Cancer. Principles and Practice of Oncology. Lippincott Company, Philadelphia, 800–834Google Scholar
  2. 2.
    UICC (1990) TNM Atlas. Illustrated Guide to the TNM/pTNM Classification of Malignant Tumours. Spiess) B et al (eds). Springer, Berlin Heidelberg New York, 126–133Google Scholar
  3. 3.
    Gudjonsson B (1987) Cancer of the Pancreas. 50 Years of Surgery. Cancer 60: 2284–2303PubMedCrossRefGoogle Scholar
  4. 4.
    Moertel CG, Frytak S, Hahn RG et al. (1981) Therapy of locally unresectable pancreatic carcinoma: A randomised comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5 fluorouracil) and high dose radiation + 5 fluorouracil. Cancer 48: 1705–1716PubMedCrossRefGoogle Scholar
  5. 5.
    Schein PS, Smith FP, Dritschillo A et al. (1983) Phase I—II trial of combined modality FAM (5fluorouracil, Adriamycin and mitomycin-C) plus split course radiation (FAM-RT-FAM) for locally edvanced gastric (LAG) and pancreatic (LAP) cancer: A Mid-Atlantic Oncology Program study. Proc Am Soc Clin Oncol 2: 216 (abstr)Google Scholar
  6. 6.
    Whittington R, Solin L, Mohiuddin M et al. (1984) Multimodality therapy of localized unresectable pancreatic adenocarcinoma. Cancer 54: 1991–1998PubMedCrossRefGoogle Scholar
  7. 7.
    The Gastrointestinal Tumor Study Group (1985) Radiation therapy combined with adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Cancer 56: 2563–2568CrossRefGoogle Scholar
  8. 8.
    Klaassen DJ, Maclntyre JM, Catton GE et al. (1985) Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil. — An Eastern Cooperative Oncology Group Study. J Clin Oncol 3: 373–378PubMedGoogle Scholar
  9. 9.
    Cohen L, Woodruff KH, Hendrickson FR et al. (1985) Response of pancreatic cancer to local irradiation with highenergy neutrons. Cancer 56: 1235–1241PubMedCrossRefGoogle Scholar
  10. 10.
    Gastrointestinal Tumor Study Group (1988) Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiation) to chemotherapy alone. J Natl Cancer Inst 80: 751–755CrossRefGoogle Scholar
  11. 11.
    Wagener DJT, van Hoessel QCGM, Yap SH, Hoogenraad WJ et al. (1989) Phase II trial of 5fluorouracil, adriamycin and cisplatin (FAP) followed by irradiation and 5-fluorouracil in locally advanced pancreatic cancer. Cancer Chemoth Pharmacol 25: 131–134CrossRefGoogle Scholar
  12. 12.
    Kamthan A, Morris JC, Chesser MR et al. (1992) Combined modality therapy for effective local control in stage II and Ill pancreatic carcinoma. Proc Am Soc Clin Oncol 11: 160 (abstr)Google Scholar
  13. 13.
    Wagener D, Rougier P, Wils J et al. (1992) Combined chemoradiotherapy for locally advanced pancreatic cancer (LAPC). Proc Am Soc Clin Oncol 11: 166 (abstr)Google Scholar
  14. 14.
    Komaki R, Wadler S, Peters MS et al. (1992) High-dose local irradiation plus prophylactic hepatic irradiation for inoperable adenocarcinoma of the pancreas. Cancer 69: 2807–2812PubMedCrossRefGoogle Scholar
  15. 15.
    Kaiser MH, Ellenberg SS (1985) Pancreatic Cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120: 899–903Google Scholar
  16. 16.
    Carter SK, Comis RL (1975) Adenocarcinoma of the pancreas: Current therapeutic approaches, prognostic variables, and criteria of response. In: Cancer Therapy Prognostic Factors and Criteria of Response. Staquet MJ (eds). Raven Press, New York, 237–253Google Scholar
  17. 17.
    Smith FP, Schein PS (1979) Chemotherapy of pancreatic cancer. Semin Oncol 6: 368–377PubMedGoogle Scholar
  18. 18.
    Loehrer PJ, Williams SD, Einhorn LH et al. (1985) Ifosfamide: An active drug in the treatment of adenocarcinoma of the pancreas. J Clin Oncol 3: 367–372Google Scholar
  19. 19.
    Bernard S, Noble S, Wilkosky T et al. (1986) A phase II study of ifosfamide (IFOS) plus n-acetyl cysteine (NAC) in metastatic measurable pancreatic adenocarcinoma (PC). Proc. Am Soc. Clin Oncol 5: 84 (abstr)Google Scholar
  20. 20.
    Ajani JA, Abbruzzese JL, Goudeau P et al. (1988) Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas. J Clin Oncol 6: 1703–1707PubMedGoogle Scholar
  21. 21.
    The Gastrointestinal Tumor Study Group (1989) Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma. Cancer 64: 2010–2013CrossRefGoogle Scholar
  22. 22.
    Wils J, Kok T, Wagener DJT et al. (1993) Phase II trial with ifosfamide in pancreatic cancer. Eur J Cancer 29 A: 290Google Scholar
  23. 23.
    Wils J, Bleiberg H, Blíjham G et al. (1985) Phase lI study of epirubicin in advanced adenocarcinoma of the pancreas. Eur J Cancer Clin Oncol 21: 191–194PubMedCrossRefGoogle Scholar
  24. 24.
    Hochster H, Green MD, Speyer JL et al. (1986) Activity of epirubicin in pancreatic carcinoma. Cancer Treat Rep 70: 299–300PubMedGoogle Scholar
  25. 25.
    Gastrointestinal Tumor Study Group (1987) Phase II trials of single agents Baker’s antifol, diâziquone, and epirubicin in advanced pancreatic cancer. Cancer Treat Rep 71: 865–867Google Scholar
  26. 26.
    Loven D, Figer A, Vigler N et al. (1989) Epirubicin in the treatment of advanced carcinoma of the pancreas. Proc Am Soc Clin Oncol 8: 113 (abstr)Google Scholar
  27. 27.
    Wils J, Kok T, Wagener DJT et al. (1993) Activity of cisplatin in adenocarcinoma of the pancreas. Eur J Cancer 29A: 203–204CrossRefGoogle Scholar
  28. 28.
    Wils JA (1991) Chemotherapy in pancreatic cancer: a rational pursuit? Anti-Cancer Drugs 2: 3–10PubMedCrossRefGoogle Scholar
  29. 29.
    Frey C, Twomey P, Keahn R et al. (1981) Randomized study of 5-FU and CCNU in pancreatic cancer. Cancer 47: 27–31PubMedCrossRefGoogle Scholar
  30. 30.
    Bukowski RM, Balcerzak SP, O’Bryan RM et al. (1983) Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. Cancer 52: 1577–1582PubMedCrossRefGoogle Scholar
  31. 31.
    Cullinan SA, Moertel CG, Fleming TR et al (1985) A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. JAMA 253: 2061–2067PubMedCrossRefGoogle Scholar
  32. 32.
    Oster MW, Gray R, Panasci L, Perry MC et al. (1986) Chemotherapy for advanced pancreatic cancer: a comparison of 5-fluorouracil, adriamycin and mitomycin (FAM) with 5-fluorouracil, streptozotocin and mitomycin ( FSM ). Cancer 57: 29–33Google Scholar
  33. 33.
    The Gastrointestinal Tumor Study Group (1986) Phase lI studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin c and two regimens of streptozotocin plus mitomycin c plus fluorouracil. J Clin Oncol 4: 1794–1798Google Scholar
  34. 34.
    Hudis C, Kelsen D, Dougherty J et al. (1990) A randomized trial of streptozotocin (S), mitomycin (M), and 5-fluorouracil (F) (SMF) vs. cisplatin (P), ara-c (A) and coffeine (C) (CAC) in advanced pancreatic cancer (PC). Proc Am Soc Clin Oncol 9: 107 (abstr)Google Scholar
  35. 35.
    Cullinan S, Moertel C, Wieand H et al. (1990) A phase Ill trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 65: 2207–2212PubMedCrossRefGoogle Scholar
  36. 36.
    Hansen R, Quebbeman E, Ritch P et al. (1988) Continuous 5-fluorouracil (5-FU) infusion in carcinoma of the pancreas: a phase II study. Am J Med Sci 295: 91–93PubMedCrossRefGoogle Scholar
  37. 37.
    Vaughn C, Chapman J, Chinn B et al. (1989) Activity of 5-fluorouracil, mitomycin C, and methyl CCNU in inoperable adenocarcinoma of the pancreas. Am J Clin Oncol 12: 49–52PubMedCrossRefGoogle Scholar
  38. 38.
    DeCaprio JA, Arbuck SG, Mayer RJ (1989) Phase lI study of weekly 5-fluorouracil (5-FU) and folinic acid (FA) in previously untreated patients with unresectable, measurable pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 5: 100 (abstr)Google Scholar
  39. 39.
    Schilder RJ, Paul AR, Walczak J et al. (1990) Phase II trial of PALA/5-fluorouracil in pancreatic cancer. Proc Am Soc Clin Oncol 9: 109 (abstr)Google Scholar
  40. 40.
    Basile M, Rougier P, Ducreux M et al. (1991) A phase II study of 5-FU continuous infusion (CI) and CDDP (P) in measurable advanced carcinoma of the pancreas (PC). Proc Am Soc Clin Oncol 10: 149 (abstr)Google Scholar
  41. 41.
    Crown J, Casper ES, Botet J et al. (1991) Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 9: 1682–1686PubMedGoogle Scholar
  42. 42.
    Rothman H, Cantrell JE, Lokich J et al. (1991) Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma. Cancer 68: 264–268PubMedCrossRefGoogle Scholar
  43. 43.
    Tian E, Ardalan B, Benedetto P et al. (1992) A phase II study of short term protracted infusion high dose 5-fluorouracil (5-FU) with leucovorin (LV) and low dose phosphonacetyl-I-aspartic acid (PALA) in pancreatic carcinoma. Proc Am Soc Clin Oncol 11: 184 (abstr)Google Scholar
  44. 44.
    Gastrointestinal Tumor Study Group (1987) Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 59: 2006–2010CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • J. Wils

There are no affiliations available

Personalised recommendations